The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: A surrogate of pelvic lymph node dissection? Follow-up analysis of a multicenter prospective phase 3 imaging trial.
 
Loic Djaileb
No Relationships to Disclose
 
Wesley Robert Armstrong
No Relationships to Disclose
 
Daniel Thompson
Research Funding - Clovis Oncology (Inst)
 
Andrei Gafita
No Relationships to Disclose
 
Andrea Farolfi
No Relationships to Disclose
 
Matthew R. Cooperberg
No Relationships to Disclose
 
Peter Carroll
Stock and Other Ownership Interests - Nutcracker Therapeutics, Inc.; Nutcracker Therapeutics, Inc.
Honoraria - BIOPHARM; Exact Sciences
Consulting or Advisory Role - Alessa Therapeutics; Francis Medical; Insightec; Nutcracker Therapeutics, Inc.; Progenics
Research Funding - Intuitive Surgical (Inst)
 
Samuel L. Washington
No Relationships to Disclose
 
Robert Evan Reiter
Stock and Other Ownership Interests - ImaginAb
Consulting or Advisory Role - Astellas Pharma
Speakers' Bureau - Bayer Schering Pharma; Genomic Health; ImaginAb; Janssen Oncology; Pfizer
Patents, Royalties, Other Intellectual Property - patents surrounding discovery of PSCA and N-cadherin, owned by UCLA (Inst)
 
Matthias Eiber
No Relationships to Disclose
 
Ken Herrmann
Leadership - Pharma15; SOFIE; Theragnostics
Stock and Other Ownership Interests - AdvanCell; Aktis Oncology; Convergent Therapeutics; Pharma15; SOFIE; Theragnostics
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; AstraZeneca; Bain Capital; Bayer; Boston Scientific; BTG; Debiopharm Group; Fusion Pharmaceuticals; GE Healthcare; Immedica; IPSEN; ITG (Inst); Janssen Oncology; Molecular Partners; Novartis; Radiopharm Theranostics; ROTOP Pharmaka (Inst); Siemens Healthineers; Telix Pharmaceuticals
 
Wofgang P Fendler
No Relationships to Disclose
 
Johannes Czernin
Leadership - SOFIE; Trethera
Stock and Other Ownership Interests - SOFIE; Trethera
Consulting or Advisory Role - Advanced Accelerator Applications; Aktis Oncology; Amgen; Jubilant Radiopharma; POINT Biopharma; RayzeBio
 
Thomas A. Hope
Stock and Other Ownership Interests - Curium Pharma; RayzeBio
Honoraria - GE Healthcare
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Curium Pharma; Ipsen; ITM Isotope Technologies Munich; Lantheus Medical Imaging
Research Funding - Advanced Accelerator Applications (Inst); Clovis Oncology (Inst); GE Healthcare (Inst); Janssen Oncology (Inst); Lantheus Medical Imaging (Inst); Philips Healthcare (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - GE Healthcare
 
Jeremie Calais
Honoraria - Advanced Accelerator Applications; Curium Pharma; EXINI Diagnostics; Novartis; Progenics; Radiomedix
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Curium Pharma; GE Healthcare; Janssen; Lantheus Medical Imaging; Novartis; POINT Biopharma; Progenics; Radiomedix; Sanofi; SOFIE; Telix Pharmaceuticals
Speakers' Bureau - Lantheus Medical Imaging
Research Funding - Progenics